Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · LASA SUPERGENERICS LTD · 31 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
LASA SUPERGENERICS LTD
NSE: LASA · BSE: 540702
NSE: LASA · BSE: 540702
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
LASA SUPERGENERICS LTD
StateQ1 FY27 filed
Last close—
Market cap—
TTM P/E · P/B · EV/EBITDA— · — · —
LASA SUPERGENERICS LTD is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 137 | 130 | 104 | 142 | 25 |
| EBITDA (ex other income) | 8 | (26) | (7) | (9) | (28) |
| margin % | 5.7 | (20.4) | (6.3) | (6.6) | (113.0) |
| Owners' profit | (5) | (39) | (22) | (15) | (34) |
| EPS, as reported (₹) | (1.32) | (15.42) | (4.34) | (2.95) | (6.80) |
| ROE % · ROCE % | (3.6) · (4.0) | (32.7) · (31.5) | (22.5) · (16.8) | (17.6) · (19.8) | (68.7) · (69.1) |
| Debt / equity (x) | 0.00 | 0.00 | 0.23 | 0.03 | 0.20 |
| Cash from operations | 10 | (34) | 2 | (3) | (23) |
| Capex | (2) | (5) | (1) | 0 | 0 |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · LASA SUPERGENERICS LTD · 31 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 39 | 33 | 39 | 20 | 3 | 2 | (0) | 1 |
| Profit before tax | (1) | 6 | (22) | (23) | (6) | (2) | (4) | (3) |
| Net profit | (3) | 5 | (14) | (21) | (6) | (3) | (4) | (4) |
| EPS (₹) | (0.64) | 1.10 | (2.85) | (4.22) | (1.25) | (0.51) | (0.83) | (0.71) |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,26,524 | 38.9 | 4.76 | 23.7 | 5.5 | 8.0 | 11.8 | 29.3 |
| DIVI S LABORATORIES LTD | 2,59,170 | 88.7 | 15.46 | 75.3 | 15.3 | 18.8 | 8.7 | 40.7 |
| TORRENT PHARMACEUTICALS L | 1,75,309 | 77.9 | 9.54 | 41.5 | 6.0 | 4.0 | 11.8 | 33.5 |
| LAURUS LABS LIMITED | 1,29,969 | 96.9 | 21.03 | 74.4 | 12.9 | 14.2 | 7.2 | 34.0 |
| ZYDUS LIFESCIENCES LTD | 1,24,301 | 27.8 | 4.20 | 15.9 | 17.3 | 18.0 | 12.4 | 24.1 |
| DR. REDDY S LABORATORIES | 1,12,892 | 40.2 | 2.89 | 18.2 | 3.4 | 4.2 | 12.1 | 19.9 |
| CIPLA LTD | 1,11,394 | 38.4 | 3.14 | 18.8 | 4.6 | 6.2 | 8.0 | 18.7 |
| MANKIND PHARMA LIMITED | 1,02,953 | 45.9 | 5.77 | 30.1 | 7.2 | 7.3 | — | 27.0 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| ROCE | (69.9) | 9.2 | 178 of 182 | 2% |
| ROE | (68.7) | 7.8 | 163 of 165 | 1% |
| Debt / Equity | 0.2 | 0.1 | 93 of 166 | 44% |
| EBITDA margin | (113.4) | 13.8 | 177 of 177 | 0% |
| Revenue growth | (93.9) | 17.1 | 155 of 161 | 4% |
| Profit growth | 83.0 | 27.3 | 44 of 158 | 73% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · LASA SUPERGENERICS LTD · 31 October 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 19 Oct 2026 · Routine Reg 74(5) compliance certificate for Sep 2026 quarter | compliance | minimal | — | — |
| 28 Sept 2026 · Trading window closed for Q2 FY27 results | compliance | minimal | — | — |
| 19 Sept 2026 · Annual Report FY26 and 11th AGM notice sent to shareholders | results | high | — | — |
| 9 Sept 2026 · Lasa Supergenerics 11th AGM notice for Sept 30, 2026 | board shareholder meetings | low | — | — |
| 9 Sept 2026 · Board approves 11th AGM notice on Sep 30, 2026 via VC | board shareholder meetings | low | — | — |
| 2 Sept 2026 · NSE seeks clarification on quarterly results compliance | regulatory legal | medium | — | — |
| 26 Aug 2026 · Board appoints Janardan Savala as Executive Director | board shareholder meetings | medium | — | — |
| 25 Aug 2026 · Whole-time Director Ganesh Potdar resigns from Lasa Supergenerics | management changes | high | — | — |
| 4 Aug 2026 · Board meeting on Aug 14 to consider Q1 FY27 results | results | low | — | — |
| 18 Jul 2026 · SDD compliance certificate for quarter ended June 2026 | compliance | minimal | — | — |
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in